Targeting mTOR with rapamycin: one dose does not fit all.

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Therapeutics

Background:

• Rapamycin's therapeutic efficacy varies due to differential mTOR suppression.
• Mammalian target of rapamycin (mTOR) exists as two complexes, mTORC1 and mTORC2.
• Phosphatidic acid (PA) levels influence mTOR complex assembly and rapamycin sensitivity.

Purpose of the Study:

• To elucidate the mechanistic basis for differential rapamycin sensitivity.
• To identify strategies for enhancing rapamycin efficacy in cancer therapy.

Main Methods:

• Mechanistic investigation of rapamycin-mammalian target of rapamycin (mTOR) interactions.
• Analysis of phosphatidic acid (PA) levels and their role in mTOR complex formation.
• Assessment of rapamycin sensitivity across varying PA concentrations.

Main Results:

• mTORC1 is sensitive to low nM rapamycin, while mTORC2 requires low µM concentrations.
• Elevated PA levels, common in cancer, increase rapamycin dosage requirements.
• Suppression of PA levels sensitizes mTORC2 to clinically achievable rapamycin concentrations.

Conclusions:

• Differential sensitivity to rapamycin is explained by distinct mTORC1/mTORC2 concentrations and PA levels.
• Targeting PA offers a strategy to enhance mTORC2 inhibition by rapamycin.
• This approach may improve rapamycin-based cancer therapeutics by increasing sensitivity.